Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 69Multiple Myeloma 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Myelodysplastic Syndromes 37Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Non-Hodgkin 33Leukemia 32Recurrence 31Lymphoma, B-Cell 30Melanoma 27Lymphoma, Large B-Cell, Diffuse 22Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hematologic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Burkitt Lymphoma 16Neoplasms 15Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Carcinoma, Renal Cell 12Head and Neck Neoplasms 11Neuroblastoma 10Leukemia, Biphenotypic, Acute 10Graft vs Host Disease 10Neoplasms, Plasma Cell 9Neoplasm Metastasis 9Colorectal Neoplasms 9Breast Neoplasms 9

Interventions

Gemcitabine 11Cisplatin 9Oxaliplatin 7Leucovorin 6Irinotecan 6Fluorouracil 5Taxes 3Radiotherapy 3Platinum 3Interleukin-12 Subunit p35 3Erlotinib Hydrochloride 3Capecitabine 3Albumin-Bound Paclitaxel 31,2-diaminocyclohexaneplatinum II citrate 3Trastuzumab 2Docetaxel 2Cyclophosphamide 2Carboplatin 2130-nm albumin-bound paclitaxel 2tipifarnib 1sargramostim 1pembrolizumab 1motexafin gadolinium 1merestinib 1guadecitabine 1fludarabine 1entinostat 1durvalumab 1dehydroftorafur 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gallbladder Neoplasms × fludarabine × Clear all
NCT07614061 2026-05-29

Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer

Shanghai Zhongshan Hospital

Phase 1 Recruiting
18 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡